GlassScriptPhysician profile
Nancy C Higgins
NPI 1164522652
$12,624.57
in general payments reported to CMS, 2019-2025
45 companies · $3,548 in 2025
The $3,548 reported for 2025 was more than what 85% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,544 · 2020: $437 · 2021: $856 · 2022: $1,455 · 2023: $2,592 · 2024: $2,193 · 2025: $3,548.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,011 · Education: $322.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,011.22 |
| Education | $321.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,809.67 | 2019-2025 | Breztri, Tezspire, Airsupra |
| Glaxosmithkline, LLC. | $2,002.01 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Jazz Pharmaceuticals INC. | $1,138.11 | 2019-2025 | |
| Actelion Pharmaceuticals US, INC. | $788.64 | 2019-2025 | Opsumit, Uptravi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $589.27 | 2019-2025 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Genzyme Corporation | $519.17 | 2019-2025 | |
| Mylan Specialty L.P. | $459.36 | 2019-2023 | Yupelri, Yupelri |
| United Therapeutics Corporation | $451.94 | 2019-2025 | Tyvaso, Tyvaso |
| Philips North America LLC | $404.01 | 2019-2025 | Vest Therapy Und, (Ak6) Vest Therapy |
| Regeneron Healthcare Solutions, INC. | $396.74 | 2019-2025 | Dupixent |
| Harmony Biosciences LLC | $372.60 | 2021-2025 | Wakix |
| Abbvie INC. | $288.90 | 2023-2025 | |
| Genentech USA, INC. | $280.65 | 2019-2024 | Xolair |
| Insmed, INC. | $262.63 | 2019-2025 | Arikayce, Brinsupri |
| Amgen INC. | $186.04 | 2022-2025 | Tezspire |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Higgins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.